Search Results 341-350 of 17292 for egfr

1. A First-in-Human (FIH) Study To Evaluate The Safety And Tolerability Of VVD-159642 In Participants With Advanced Solid Tumors - Mayo Clinic

   ... (EGFR) alteration as per local/historical testing; or human epidermal growth factor receptor 2 (HER2) overexpression (immunohistochemistry \[IHC\] 3+ or IHC ...

2. Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer - Mayo Clinic

   NOTE: If the results of the central EGFR testing are negative, but the ALK testing was not able to be completed by the ALCHEMIST central lab, the ALK status ...

3. A Phase 1/2 Study To Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Efficacy Of HMB-001 In Glanzmann Thrombasthenia - Mayo Clinic

   ... (eGFR) of ≥ 45 ml/min/1.73m2 at Screening 2. An aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin ≤ 1.5 upper limit of ...

4. A Study To Evaluate Effectiveness And Safety Of AL001 In Frontotemporal Dementia - Mayo Clinic

   Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m^2, according to the re-expressed abbreviated (four-variable) Modification of Diet in Renal Disease ...

5. A Study Of MBG453 In Combination With Azacitidine And Venetoclax In AML Patients Unfit For Chemotherapy - Mayo Clinic

   renal impairment (eGFR ≥ 30 ml/min/1.73m^2 to 45 30 ml/min/1.73m^2); or; any other comorbidity (to be documented in the CRF) that the physician judges to be ...

6. Senescence In Chronic Kidney Disease - Mayo Clinic

   Chronic kidney disease estimated glomerular filtration rate (eGFR)15-45 ml/min/1.73m2. Diabetes mellitus and taking diabetes medications. Exclusion Criteria ...

7. A Study to Evaluate Yttrium-90 Therapy for Radiation Lobectomy - Mayo Clinic

   Patients with an eGFR < 30 mL/min/m^2. Must not have any significant life-threatening extra-hepatic disease or lifethreatening secondary malignancies ...

8. A Study of Sporadic Angiomyolipomas Growth Kinetics While on Everolimus - Mayo Clinic

   Renal Function epidermal growth factor receptor (eGFR) ≥ 30 mL/min via calculated creatinine clearance; Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 ...

9. Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination with Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer - Mayo Clinic

   Subjects with EGFR or ALK mutation are eligible if they have previously received EGFR or ALK inhibitor(s) respectively. Exclusion Criteria: Previous ...

10. Clinical Trial Of The ATM-Inhibitor WSD0628 In Combination With Radiation Therapy For Recurrent Brain Tumors

    Creatinine ≤ 1.5 x ULN or estimated glomerular filtration rate (eGFR) ≥ 60 mL/minute. Minimum life expectancy of at least 3 months. Willing to take light ...